[go: up one dir, main page]

BRPI0811044A2 - 2-morfolin-4-il-pirimidinas como inibidores de p13k. - Google Patents

2-morfolin-4-il-pirimidinas como inibidores de p13k.

Info

Publication number
BRPI0811044A2
BRPI0811044A2 BRPI0811044-1A2A BRPI0811044A BRPI0811044A2 BR PI0811044 A2 BRPI0811044 A2 BR PI0811044A2 BR PI0811044 A BRPI0811044 A BR PI0811044A BR PI0811044 A2 BRPI0811044 A2 BR PI0811044A2
Authority
BR
Brazil
Prior art keywords
morfolin
pyrimidines
inhibitors
Prior art date
Application number
BRPI0811044-1A2A
Other languages
English (en)
Inventor
Paul John Goldsmith
Timothy Colin Hancox
Neil Anthony Pegg
Stephen Joseph Shuttleworth
Jonathan Martin Large
Edward Mcdonald
Original Assignee
Hoffmann La Roche
Cancer Res Inst
Cancer Res Inst Royal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Cancer Res Inst, Cancer Res Inst Royal filed Critical Hoffmann La Roche
Publication of BRPI0811044A2 publication Critical patent/BRPI0811044A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0811044-1A2A 2007-04-12 2008-04-14 2-morfolin-4-il-pirimidinas como inibidores de p13k. BRPI0811044A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0707087.3A GB0707087D0 (en) 2007-04-12 2007-04-12 Pharmaceutical compounds
PCT/GB2008/001294 WO2008125835A1 (en) 2007-04-12 2008-04-14 2-morpholin-4-yl-pyrimidines as pi3k inhibitors

Publications (1)

Publication Number Publication Date
BRPI0811044A2 true BRPI0811044A2 (pt) 2014-12-09

Family

ID=38116624

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811044-1A2A BRPI0811044A2 (pt) 2007-04-12 2008-04-14 2-morfolin-4-il-pirimidinas como inibidores de p13k.

Country Status (12)

Country Link
US (1) US20100210646A1 (pt)
EP (1) EP2152693A1 (pt)
JP (1) JP2010523638A (pt)
KR (1) KR20100016432A (pt)
CN (1) CN101821255A (pt)
AU (1) AU2008237717A1 (pt)
BR (1) BRPI0811044A2 (pt)
CA (1) CA2683622A1 (pt)
GB (1) GB0707087D0 (pt)
IL (1) IL201367A0 (pt)
MX (1) MX2009010884A (pt)
WO (1) WO2008125835A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
NZ590777A (en) 2008-07-31 2012-11-30 Genentech Inc PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE FOR INHIBITING mTOR
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
JP5572715B2 (ja) 2009-11-12 2014-08-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト N−7置換プリン及びピラゾロピリミジン化合物、組成物及び使用方法
ES2596654T3 (es) 2009-11-12 2017-01-11 F. Hoffmann-La Roche Ag Compuestos de purina N-9-sustituida, composiciones y métodos de uso
EP2519102B1 (en) * 2009-12-28 2016-10-19 Development Center For Biotechnology NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PT2790705T (pt) 2011-12-15 2018-01-24 Novartis Ag Utilização de inibidores da atividade ou função de pi3k
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US7423148B2 (en) 2002-11-21 2008-09-09 Chiron Corporation Small molecule PI 3-kinase inhibitors and methods of their use
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds

Also Published As

Publication number Publication date
MX2009010884A (es) 2009-12-14
WO2008125835A1 (en) 2008-10-23
AU2008237717A1 (en) 2008-10-23
US20100210646A1 (en) 2010-08-19
JP2010523638A (ja) 2010-07-15
IL201367A0 (en) 2010-05-31
CA2683622A1 (en) 2008-10-23
CN101821255A (zh) 2010-09-01
KR20100016432A (ko) 2010-02-12
EP2152693A1 (en) 2010-02-17
GB0707087D0 (en) 2007-05-23

Similar Documents

Publication Publication Date Title
BRPI0811044A2 (pt) 2-morfolin-4-il-pirimidinas como inibidores de p13k.
CY2020023I2 (el) Αναστολεiς βητα-λακταμασων
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
NO2021006I1 (no) Quofenix, delafloksacin
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0906973A2 (pt) Compostos e composições como inibidores de cinase.
BRPI0814797A2 (pt) Inibidores dna-pk
BRPI1010301A2 (pt) composição.
BRPI0906764A2 (pt) Processos
BR112012000525A2 (pt) inibidores da bace
BRPI0917980A2 (pt) subcanalização com aumento de potência
BRPI0811639A2 (pt) Cicloaquilaminas fenil substituídas como inibidores da recaptação de monoamina
FI20085260A0 (fi) Tulisija
BRPI0907925A2 (pt) Ativadores de glicoquinase.
BRPI0918564A2 (pt) inibidores
EP2344471A4 (en) 7-PIPERIDINALKYL-3,4-dihydroquinolone DERIVATIVE
BRPI0912475A8 (pt) compostos como inibidores de quinase
DK2116775T3 (da) Kogesektion
BR112012001070A2 (pt) inibidores de ativação de complementos
BRPI0810175A2 (pt) Inibidores pirididopirinidinona de p13k alfa
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
IT1396487B1 (it) Convogliatore.
BRPI0914936A2 (pt) naftiridininonas como inibidores de aurora quinase
BRPI1016192A2 (pt) derivados de soxazol.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]